NOGO-A in Multiple Sclerosis FTIH

Multiple Sclerosis Clinical Trial

Official title:

A Randomized, Single-blind (Investigator and Subject), Placebo-controlled, Single Ascending Dose Study Exploring the Preliminary Safety, Tolerability, and Pharmacokinetics of GSK1223249 Administered by Intravenous (IV) Infusion to Subjects With Relapsing Forms of Multiple Sclerosis, Not on Disease Modifying Therapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01424423
• Other study ID #: 112988
• Status: Terminated
• Phase: Phase 1
• First received: June 9, 2011
• Last updated: September 19, 2017
• Start date: February 11, 2010
• Est. completion date: August 26, 2010

Study information

• Verified date: September 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The drug being tested in this study is GSK1223249. The drug works by inhibiting a protein that prevents nerve growth.

The trial is expected to involve approximately 36 patients. The study objective is to investigate the tolerability, safety and the way the body handles GSK1223249 after a range of single doses in patients with Multiple Sclerosis (MS).

Description:

This is a phase I study of GSK1223249. The study design is randomized, placebo-controlled, double-blind, sequential dose escalation, single dose administration. Approximately 36 patients with relapsing forms of Multiple Sclerosis (having had at least two relapses over the previous 24 months, OR at least one relapse within the last 12 months, OR having had at least one documented gadolinium-enhancing lesion on brain magnetic resonance imaging (MRI) within 12 months prior to Screening) will be enrolled.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: August 26, 2010
• Est. primary completion date: August 26, 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Suitable as determined by the Principal Investigator, based on his/her overall evaluation. A patient with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.

• Diagnosed with a relapsing form of MS defined as either

• Relapsing Remitting MS according to revised McDonald Criteria [McDonald, 2001; Polman, 2005] plus any one of the following:

Occurrence of at least one relapse in the previous 12 months OR at least 2 relapses in the previous 24 months OR at least one documented Gd-enhancing lesion by magnetic resonance imaging (MRI) within 12 months prior to screening.

OR

-Secondary Progressive MS, plus any one of the following: Occurrence of at least one relapse in the previous 12 months OR at least 2 relapses in the previous 24 months OR at least one documented Gd-enhancing lesion by magnetic resonance imaging (MRI) within 12 months prior to screening.

• Expanded Disability Status Scale (EDSS) score =5.5

• Male or female between 18 and 55 years of age inclusive, at the time of signing the informed consent.

Exclusion Criteria:

• Abnormal baseline blood tests

• Treatment with interferon-beta-1b (Betaferon), interferon-beta-1a (Rebif or Avonex), or glatiramer acetate (Copaxone) within 90 days of dosing.

• Treatment with methylprednisolone or any other systemic steroids within 60 days of dosing.

• Treatment within the past 12 months or currently with any of the following agents:

cyclosporine, azathioprine, methotrexate, cladribine, natalizumab (Tysabri®) or other monoclonal antibodies, murine protein, T-cell vaccination, plasmapheresis, IVI gG, ,stem cell transplantation.

• History of intolerance to acetominophen, ibuprofen, naproxen or any other non-steroidal anti-inflammatory agent which would preclude use of at least one of these during the study.

• Previous history of anaphylaxis, severe allergic reaction, or hypersensitivity to albumin or a protein-based therapeutic, including natalizumab (Tysabri) or any other monoclonal antibody. History of hypersensitivity to any of the components of the formulation.

• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result.

• Patients with evidence of dementia or psychiatric illness which, in the Investigator's opinion, is likely to prevent them from a full understanding of and/or compliance with the study requirements and procedures.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• Placebo
Placebo
• GSK1223249
I.V. Infusion

Locations

Country	Name	City	State
Australia	GSK Investigational Site	Heidelberg	Victoria

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The preliminary safety and tolerability of single doses of GSK1223249	changes in Vital signs, Electocardiogram, safety laboratory samples, adverse event (AE), neurological examination and MS relapses	screening, baseline (pre-dose) and up to 84 days post dose
Secondary	Single dose pharmacokinetics.	(AUC(0-8)	screening, baseline (pre-dose) and up to 84 days post dose

External Links

•   Results for study 112988 can be found on the GSK Clinical Study Register.